Cerevel Therapeutics Holdings, Inc. Financials

Market Capitalization $7.46 Billion as of July 1, 2024

Valuations Metrics as of May. 5, 2024

Trailing PE
Forward PE	-15.14
Price to Sales TTM	$
Price to Book MRQ	$11.45
Enterprise to Revenue
Enterprise to EBITDA	-16.34

Financial Reports as of Dec. 31, 2023

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2023-12-31
Profit Margin	0.00%
Operating Margin	0.00%
Return on Assets TTM	-24.73%
Return on Equity TTM	-72.44%

Income Statement

Revenue TTM	$0
Revenue per Share TTM	$
Quarterly Revenue Growth	%
Gross Profit TTM	$0
EBITDA	$-441,638,016
Net Income to Common TTM	$-432,841,984
Diluted EPS TTM	$-2.67
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	$990,964,992
Total Cash per Share MRQ	$5.46
Total Debt MRQ	$
Total Debt to Equity MRQ	71.36
Current Ratio MRQ	10.92
Book Value per Share MRQ	$3.72

Cash Flow

Operating Cash Flow TTM	$-342,300,992
Levered Free Cash Flow TTM	$-198,158,000

CERE Stock Info as of May. 5, 2024

Stock Statistics

Shares Outstanding	181,888,992
Float Shares	77,226,294
Avg 10 Volume	944,052
Avg 30 Volume	None
Shares Short	7,923,837
Short Ratio	5.97
Short % of Shares	9.15%
% Held by Insiders	15.30%
% Held by Institutions	86.13%

Stock Price Summary

Beta	1.49
Fifty Two Week Low	$19.59
Fifty Two Week High	$43.59
Fifty Two Week Change	23.06%
Day 50 MA	$41.93
Day 200 MA	$33.13

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date